Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model

Sharma N 1 , Khurana N 2 , Muthuraman A 3 , Utreja P 4

Affiliations 

  • 1 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144 411, India; Akal College of Pharmacy and Technical Education, Gursagar Mastuana Sahib, Sangrur, Punjab, 148 001, India; Research Scholar, I.K. Gujral Punjab Technical University, Kapurthala, Punjab, 144 603, India
  • 2 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144 411, India
  • 3 Akal College of Pharmacy and Technical Education, Gursagar Mastuana Sahib, Sangrur, Punjab, 148 001, India; Asian Institute of Medicine, Science and Technology, Malaysia
  • 4 Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Ludhiana, Punjab, 142 021, India. Electronic address: drutreja@gmail.com
Eur J Pharmacol, 2021 Jul 15;903:174112.
PMID: 33901458 DOI: 10.1016/j.ejphar.2021.174112

Abstract

In the present study, we investigated the anti-Parkinson's effect of vanillic acid (VA) (12 mg/kg, 25 mg/kg, 50 mg/kg p.o.) against rotenone (2 mg/kg s.c.) induced Parkinson's disease (PD) in rats. The continuous administration of rotenone for 35 days resulted in rigidity in muscles, catalepsy, and decrease in locomotor activity, body weight, and rearing behaviour along with the generation of oxidative stress in the brain (rise in the TBARS, and SAG level and reduced CAT, and GSH levels). Co-treatment of VA and levodopa-carbidopa (100 mg/kg + 25 mg/kg p.o.) lead to a significant (P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications